Mark Cockett

Mark Cockett has over 35 years of work experience in the pharmaceutical and biotechnology industry. Mark is currently the CEO and President of R&D at Alphina Therapeutics since May 2022. Prior to this, Mark was the President of MIC Scientific Consulting from March 2022. From 2016 to 2022, they served as the VP and Head of Discovery at ViiV Healthcare, where they led the discovery organization and played a crucial role in delivering new HIV molecules into clinical development. Mark also served as the site head for the Branford, CT R&D site. Before joining ViiV Healthcare, Mark worked at Bristol-Myers Squibb for over 16 years, holding several leadership positions. Mark was the VP of Discovery Infectious Diseases, where they led a team of scientists focusing on the discovery and development of antiviral therapies. Mark also served as the Vice President of Applied Genomics, responsible for building and evolving the Applied Genomic department and supporting genomic capabilities across multiple therapeutic areas. Prior to that, they worked at Wyeth Pharmaceuticals as the Director of Molecular & Cellular Biology, Neuroscience Dept., where they led a group of molecular biologists and contributed to the progression of multiple drug candidates. Mark's career began at Celltech PLC, where they worked as a Research Scientist, specializing in the expression of recombinant molecules in mammalian cells and establishing the company's expertise in mammalian cell expression.

Mark Cockett holds a Ph.D. in Molecular and Cell Biology from The Open University. Prior to this, they earned a Bachelor of Science degree in Biochemistry from the Institute of Biology - Royal Society of Biology. Specific start and end dates for these educational pursuits were not provided.